Brazilian society of rheumatology methodological guide for the development of evidence-based clinical guidelines in rheumatology.

Clinical practice guidelines (CPG) are developed to align standards of health care around the world, aiming to reduce the incidence of misconducts and enabling more effective use of health resources. Considering the complexity, cost, and time involved in formulating CPG, strategies should be used to facilitate and guide authors through each step of this process. The main objective of this document is to present a methodological guide prepared by the Epidemiology Committee of the Brazilian Society of Rheumatology for the elaboration of CPG in rheumatology. Through an extensive review of the literature, this study compiles the main practical recommendations regarding the following steps of CPG drafting: distribution of working groups, development of the research question, search, identification and selection of relevant studies, evidence synthesis and quality assessment of the body of evidence, the Delphi methodology for consensus achievement, presentation and dissemination of the recommendations, CPG quality assessment and updating. This methodological guide serves as an important tool for rheumatologists to develop reliable and high-quality CPG, standardizing clinical practices worldwide.

Brazilian society of rheumatology methodological guide for the development of evidence-based clinical guidelines in rheumatology

Abstract Clinical practice guidelines (CPG) are developed to align standards of health care around the world, aiming to reduce the incidence of misconducts and enabling more effective use of health resources. Considering the complexity, cost, and time involved in formulating CPG, strategies should be used to facilitate and guide authors through each step of this process. The main objective of this document is to present a methodological guide prepared by the Epidemiology Committee of the Brazilian Society of Rheumatology for the elaboration of CPG in rheumatology. Through an extensive review of the literature, this study compiles the main practical recommendations regarding the following steps of CPG drafting: distribution of working groups, development of the research question, search, identification and selection of relevant studies, evidence synthesis and quality assessment of the body of evidence, the Delphi methodology for consensus achievement, presentation and dissemination ofthe recommendations, CPG quality assessment and updating. This methodological guide serves as an important tool for rheumatologists to develop reliable and high-quality CPG, standardizing clinical practices worldwide.

Suicide risk in systemic lupus erythematosus: a narrative review / Risco de suicidio no lúpus eritematoso sistêmico: uma revisão narrativa

Introduction: the restrictions imposed by the disease and the perception of personal and social losses related to its course, despite the medical and scientific advances, reinforce fear and generate intense suffering in lupus patients. Psychiatric comorbidities, especially major depressive episodes, are highly prevailing during the course of systemic lupus erythematosus. Among them, suicide is a behavior that is much more common then we believe. Objective: to perform a narrative review on suicidal behavior associated with systemic erythematosus lupus (SLE). Results: studies have shown an increased risk of suicide among patients with chronic diseases and psychiatric disorder, especially depression. However, suicide occurrence cannot be attributed only to a higher prevalence of depression and other mental illnesses. It is necessary to learn more about the suicide risk factors that can be present in patients with lupus to work on a secondary prevention, and avoid not only the premature loss of lives but also the additional suffering of families and surrounding communities. The coordination between the studies on suicidal behavior and its complex network of individual and sociocultural factors and the studies on this multisystem autoimmune disease with a wide manifestation spectrum, which is lupus, creates a new and important field of research. Conclusion: non-psychiatrist office-based physicians, health clinics, or wards dedicated to the treatment of SLE should be able to recognize and handle the suicide risk factors on their patients in order to reduce the suffering caused by this disease.

Introdução: as restrições impostas pela doença e a percepção de perdas pessoais e sociais relacionadas ao seu curso, apesar dos avanços médicos e científicos, reforçam o medo e geram sofrimento intenso em pacientes com lúpus. As comorbidades psiquiátricas, especialmente os episódios depressivos maiores, são altamente prevalentes durante o curso do lúpus eritematoso sistêmico. Entre eles, o suicídio é um comportamento muito mais comum do que acreditamos. Objetivo: realizar uma revisão narrativa sobre o transtorno do suicídio no campo do lúpus. Resultados: estudos têm mostrado um risco aumentado de suicídio entre pacientes com doenças crônicas e distúrbios psiquiátricos, especialmente a depressão. No entanto, a ocorrência de suicídio não pode ser atribuída apenas a uma maior prevalência de depressão e outras doenças mentais. É necessário aprender mais sobre os fatores de risco de suicídio que podem estar presentes em pacientes com lúpus para trabalhar em uma prevenção secundária e evitar, não apenas a perda prematura de vidas, mas também o sofrimento adicional das famílias e comunidades vizinhas. A coordenação entre os estudos sobre comportamentos suicidas e sua complexa rede de fatores individuais e socioculturais e os estudos sobre esta doença auto imune multissistêmica com um amplo espectro de manifestação, que é lúpus, criam um novo e importante campo de pesquisa. Conclusão: os médicos não psiquiatras que trabalham em consultórios, clínicas e enfermarias dedicadas ao tratamento do lúpus devem ser capazes de pesquisar, identificar e lidar com os fatores de risco suicida em seus pacientes, a fim de reduzir o sofrimento causado por esta doença.

Chorea in primary antiphospholipid syndrome is associated with rheumatic fever.

The aim of the study is to evaluate the frequency of chorea in a cohort of primary antiphospholipid syndrome (PAPS) patients and their possible clinical and laboratory associations. The records of 88 PAPS patients, fulfilling Sapporo criteria, followed up at the rheumatology outpatient clinic, were analyzed in order to determine the frequency of chorea. Risk factors for chorea, clinical manifestations, associated comorbidities, serologic features and treatment strategies were analyzed. Eighty-eight PAPS patients were evaluated. Mean age was 40.6 ± 11.1 years, and 91% of them were Caucasian and 91% women. Four (4.5%) patients with chorea were identified: 2 of them (50%) had only one chorea episode and 2 (50%) had recurrent chorea. All patients had chorea onset before PAPS diagnosis. Mean age, gender and ethnical distribution were comparable in groups with or without seizures (P > 0.05). Interestingly, the comparison of the 4 PAPS patients with chorea with those without this abnormality (n = 84) demonstrated a lower BMI [21.1 (18-24.2) vs. 27.5 (17.5-40.9) kg/m(2), P = 0.049] and frequency of venous events (0 vs. 63.1%, P = 0.023) in the first group. A higher frequency of rheumatic fever (75% vs. 0, P < 0.001) and thrombocytopenia (75 vs. 21.4%, P = 0.041) was observed in PAPS individuals with chorea. Both groups were alike regarding the other clinical APS manifestations, disease duration, risk factors for cerebrovascular diseases, use of drugs and antiphospholipid antibodies (P > 0.05). This study demonstrated that 4.5% of PAPS patients had chorea, predominately before PAPS diagnosis, and this neurological abnormality was associated with rheumatic fever and thrombocytopenia. These data reinforce the need for RF diagnosis in those PAPS patients with chorea.